

Clinical Oversight Review Board (CORB) Criteria for Prescribing Taliglucerase alfa (Elelyso)

Notes:

- Quantity Limits: No

Non-Formulary **taliglucerase alfa (Elelyso)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria and criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously:

- Prescriber is a geneticist.
- Patient has a diagnosis of Type 1 Gaucher disease
- Patient has signs and symptoms of symptomatic disease, including: anemia, thrombocytopenia, skeletal disease, or visceromegaly (*liver or spleen enlargement*)

kp.org

Revised: 08/08/24
Effective: 10/17/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest